Literature DB >> 27444227

Non-coding RNAs as drug targets.

Masayuki Matsui1, David R Corey1.   

Abstract

Most of the human genome encodes RNAs that do not code for proteins. These non-coding RNAs (ncRNAs) may affect normal gene expression and disease progression, making them a new class of targets for drug discovery. Because their mechanisms of action are often novel, developing drugs to target ncRNAs will involve equally novel challenges. However, many potential problems may already have been solved during the development of technologies to target mRNA. Here, we discuss the growing field of ncRNA - including microRNA, intronic RNA, repetitive RNA and long non-coding RNA - and assess the potential and challenges in their therapeutic exploitation.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27444227      PMCID: PMC5831170          DOI: 10.1038/nrd.2016.117

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  140 in total

Review 1.  Sensible use of antisense: how to use oligonucleotides as research tools.

Authors:  K J Myers; N M Dean
Journal:  Trends Pharmacol Sci       Date:  2000-01       Impact factor: 14.819

2.  Keeping the biotechnology of antisense in context.

Authors:  C A Stein
Journal:  Nat Biotechnol       Date:  1999-03       Impact factor: 54.908

Review 3.  Oligonucleotide therapeutics: chemistry, delivery and clinical progress.

Authors:  Vivek K Sharma; Jonathan K Watts
Journal:  Future Med Chem       Date:  2015-10-29       Impact factor: 3.808

4.  Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat.

Authors:  A Mankodi; E Logigian; L Callahan; C McClain; R White; D Henderson; M Krym; C A Thornton
Journal:  Science       Date:  2000-09-08       Impact factor: 47.728

Review 5.  MicroRNA-based therapy and breast cancer: A comprehensive review of novel therapeutic strategies from diagnosis to treatment.

Authors:  Parham Jabbarzadeh Kaboli; Asmah Rahmat; Patimah Ismail; King-Hwa Ling
Journal:  Pharmacol Res       Date:  2015-05-07       Impact factor: 7.658

Review 6.  Bcl-2 antisense in the treatment of human malignancies: a delusion in targeted therapy.

Authors:  Bjørn Tore Gjertsen; Therese Bredholt; Nina Anensen; Olav Karsten Vintermyr
Journal:  Curr Pharm Biotechnol       Date:  2007-12       Impact factor: 2.837

Review 7.  Guided by RNAs: X-inactivation as a model for lncRNA function.

Authors:  John E Froberg; Lin Yang; Jeannie T Lee
Journal:  J Mol Biol       Date:  2013-06-28       Impact factor: 5.469

8.  Analysis of nuclear RNA interference in human cells by subcellular fractionation and Argonaute loading.

Authors:  Keith T Gagnon; Liande Li; Bethany A Janowski; David R Corey
Journal:  Nat Protoc       Date:  2014-07-31       Impact factor: 13.491

9.  The transcriptional landscape of the mammalian genome.

Authors:  P Carninci; T Kasukawa; S Katayama; J Gough; M C Frith; N Maeda; R Oyama; T Ravasi; B Lenhard; C Wells; R Kodzius; K Shimokawa; V B Bajic; S E Brenner; S Batalov; A R R Forrest; M Zavolan; M J Davis; L G Wilming; V Aidinis; J E Allen; A Ambesi-Impiombato; R Apweiler; R N Aturaliya; T L Bailey; M Bansal; L Baxter; K W Beisel; T Bersano; H Bono; A M Chalk; K P Chiu; V Choudhary; A Christoffels; D R Clutterbuck; M L Crowe; E Dalla; B P Dalrymple; B de Bono; G Della Gatta; D di Bernardo; T Down; P Engstrom; M Fagiolini; G Faulkner; C F Fletcher; T Fukushima; M Furuno; S Futaki; M Gariboldi; P Georgii-Hemming; T R Gingeras; T Gojobori; R E Green; S Gustincich; M Harbers; Y Hayashi; T K Hensch; N Hirokawa; D Hill; L Huminiecki; M Iacono; K Ikeo; A Iwama; T Ishikawa; M Jakt; A Kanapin; M Katoh; Y Kawasawa; J Kelso; H Kitamura; H Kitano; G Kollias; S P T Krishnan; A Kruger; S K Kummerfeld; I V Kurochkin; L F Lareau; D Lazarevic; L Lipovich; J Liu; S Liuni; S McWilliam; M Madan Babu; M Madera; L Marchionni; H Matsuda; S Matsuzawa; H Miki; F Mignone; S Miyake; K Morris; S Mottagui-Tabar; N Mulder; N Nakano; H Nakauchi; P Ng; R Nilsson; S Nishiguchi; S Nishikawa; F Nori; O Ohara; Y Okazaki; V Orlando; K C Pang; W J Pavan; G Pavesi; G Pesole; N Petrovsky; S Piazza; J Reed; J F Reid; B Z Ring; M Ringwald; B Rost; Y Ruan; S L Salzberg; A Sandelin; C Schneider; C Schönbach; K Sekiguchi; C A M Semple; S Seno; L Sessa; Y Sheng; Y Shibata; H Shimada; K Shimada; D Silva; B Sinclair; S Sperling; E Stupka; K Sugiura; R Sultana; Y Takenaka; K Taki; K Tammoja; S L Tan; S Tang; M S Taylor; J Tegner; S A Teichmann; H R Ueda; E van Nimwegen; R Verardo; C L Wei; K Yagi; H Yamanishi; E Zabarovsky; S Zhu; A Zimmer; W Hide; C Bult; S M Grimmond; R D Teasdale; E T Liu; V Brusic; J Quackenbush; C Wahlestedt; J S Mattick; D A Hume; C Kai; D Sasaki; Y Tomaru; S Fukuda; M Kanamori-Katayama; M Suzuki; J Aoki; T Arakawa; J Iida; K Imamura; M Itoh; T Kato; H Kawaji; N Kawagashira; T Kawashima; M Kojima; S Kondo; H Konno; K Nakano; N Ninomiya; T Nishio; M Okada; C Plessy; K Shibata; T Shiraki; S Suzuki; M Tagami; K Waki; A Watahiki; Y Okamura-Oho; H Suzuki; J Kawai; Y Hayashizaki
Journal:  Science       Date:  2005-09-02       Impact factor: 47.728

10.  The reality of pervasive transcription.

Authors:  Michael B Clark; Paulo P Amaral; Felix J Schlesinger; Marcel E Dinger; Ryan J Taft; John L Rinn; Chris P Ponting; Peter F Stadler; Kevin V Morris; Antonin Morillon; Joel S Rozowsky; Mark B Gerstein; Claes Wahlestedt; Yoshihide Hayashizaki; Piero Carninci; Thomas R Gingeras; John S Mattick
Journal:  PLoS Biol       Date:  2011-07-12       Impact factor: 8.029

View more
  295 in total

Review 1.  RNA Structural Differentiation: Opportunities with Pattern Recognition.

Authors:  Christopher S Eubanks; Amanda E Hargrove
Journal:  Biochemistry       Date:  2018-12-18       Impact factor: 3.162

Review 2.  Understanding the mechanistic basis of non-coding RNA through molecular dynamics simulations.

Authors:  Giulia Palermo; Lorenzo Casalino; Alessandra Magistrato; J Andrew McCammon
Journal:  J Struct Biol       Date:  2019-03-15       Impact factor: 2.867

Review 3.  Face-time with TAR: Portraits of an HIV-1 RNA with diverse modes of effector recognition relevant for drug discovery.

Authors:  Sai Shashank Chavali; Rachel Bonn-Breach; Joseph E Wedekind
Journal:  J Biol Chem       Date:  2019-05-12       Impact factor: 5.157

4.  Integrative analysis of differential circular RNA and long non-coding RNA profiles and associated competing endogenous RNA networks in esophageal squamous cell carcinoma.

Authors:  Jiang-Feng Shen; Jin-Feng Ge; Shi-Ying Zheng; Dong Jiang
Journal:  Funct Integr Genomics       Date:  2021-01-07       Impact factor: 3.410

Review 5.  Antisense technology: an overview and prospectus.

Authors:  Stanley T Crooke; Brenda F Baker; Rosanne M Crooke; Xue-Hai Liang
Journal:  Nat Rev Drug Discov       Date:  2021-03-24       Impact factor: 84.694

6.  Identification of hub lncRNA ceRNAs in multiple sclerosis based on ceRNA mechanisms.

Authors:  Yanjun Ding; Taotao Li; Xinwei Yan; Mintian Cui; Chao Wang; Situo Wang; Fengmin Zhang; Ruijie Zhang
Journal:  Mol Genet Genomics       Date:  2021-01-28       Impact factor: 3.291

Review 7.  The Ku complex: recent advances and emerging roles outside of non-homologous end-joining.

Authors:  Sanna Abbasi; Gursimran Parmar; Rachel D Kelly; Nileeka Balasuriya; Caroline Schild-Poulter
Journal:  Cell Mol Life Sci       Date:  2021-04-15       Impact factor: 9.261

Review 8.  Targeting RNA in mammalian systems with small molecules.

Authors:  Anita Donlic; Amanda E Hargrove
Journal:  Wiley Interdiscip Rev RNA       Date:  2018-05-03       Impact factor: 9.957

9.  MicroRNA-183 promotes the proliferation and metastasis of renal cell carcinoma through targeting Dickkopf-related protein 3.

Authors:  Xiao-Long Zhang; Gang Xu; Yi Zhou; Jia-Jun Yan
Journal:  Oncol Lett       Date:  2018-02-08       Impact factor: 2.967

Review 10.  Emerging roles for ncRNAs in alcohol use disorders.

Authors:  R Dayne Mayfield
Journal:  Alcohol       Date:  2017-04-15       Impact factor: 2.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.